The shRNA-Ptpn2 system combined with DOX was then administered as immuno-combined chemotherapy to a mouse model of melanoma via nanoparticles, and the therapeutic efficacy was assessed (Figure 1). The gene discussed is PTPN2; the disease is melanoma.